JSC
JAZZ icon

Jackson Square Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Jackson Square Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-22
Closed -$3K – 364
2019
Q4 		$3K Buy
+22
New +$2.99K ﹤0.01% 363

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Jackson Square Capital's JAZZ Position: Q1 2020 in Review

Jackson Square Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 22 shares — an estimated $3K sold.

Jackson Square Capital first reported a position in JAZZ in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

  • Jackson Square Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Jackson Square Capital sold 22 Jazz Pharmaceuticals shares in Q1 2020, an estimated $3K.
  • Jackson Square Capital first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Jackson Square Capital's Jazz Pharmaceuticals position peaked at $3K in Q4 2019.
  • 407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Jackson Square Capital's 13F filing for Q1 2020, filed 15 May 2020.